Maxalt Rapitab

Rizatriptan, the active ingredient in Maxalt Rapitab, is a triptan presented as a tablet for oral use. It treats acute migraine attacks in adults, providing rapid relief of headache and associated symptoms. GNH USA supplies Maxalt Rapitab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rizatriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the acute treatment of migraine. - Migraine without aura: relieves headache pain, nausea and photophobia during an acute attack. - Migraine with aura: reduces severity of headache and associated neurological symptoms. - Acute migraine attack: provides rapid symptom control when taken at onset of migraine.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest discomfort or tightness. - Tingling or numbness in the fingers or toes. - Dizziness or light‑headedness. - Fatigue or general weakness. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Serotonin syndrome, especially when combined with other serotonergic agents. - Severe allergic reactions, including anaphylaxis. - Cardiac ischemia or myocardial infarction in patients with underlying heart disease.

Before prescribing Rizatriptan, clinicians should evaluate cardiovascular risk and concomitant medication use. - Cardiovascular disease: avoid in patients with uncontrolled coronary artery disease or recent myocardial infarction. - History of stroke or transient ischemic attack: contraindicated. - Concurrent MAOI therapy: discontinue MAOI at least 14 days before use. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Age restrictions: not established for children; use only in adults. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Rizatriptan can interact with several drug classes, altering its safety or efficacy.

Major Interactions (Avoid): - Ergot derivatives: combined vasoconstriction may precipitate serious vascular events. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs) or other serotonergic agents: heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise rizatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Other triptans or vasoconstrictors: additive vascular effects require careful monitoring.